Withdrawal of non-binding proposal

26^th Aug 2015

In the Company’s announcement of the conclusion of its strategic review released on 18 August, 2015, reference was made to a non-binding preliminary proposal of US$110 million for the Company’s Point-of-Care business. That proposal has now been withdrawn.

The proposals referenced in the Company’s announcements released on 24 August, 2015 are not affected.

Back to Listing

EKF Diagnostics

EKF Diagnostics Holdings plc is a manufacturer and distrbutor of IVD products. It has three core divisions: Point of Care including hemoglobin and HbA1c analyzers; Central Laboratory including the manufacture of enzymes and clinical chemistry; and Molecular Diagnostics which incorporates a unique DNA enrichment technology, PointMan, and a portfolio of molecular testing services.

News & events

EKF launches handheld veterinary lactate analyzer

EKF to showcase POCT connectivity solutions at MEDICA 2022

Powerful digital connectivity products and contract manufacturing capabilities in Hall 3 at Stand B69

EKF introduces hand-held hemoglobin analyzer with secure POC connectivity

DiaSpect Tm POC hemoglobin analyzer now powered by EKF Link digital connectivity solution

Medica 2022

Medica is the world’s largest medical trade fair. For more than 40 years it has been firmly established on every professional's calendar attracting over 40,000 delegates and over 5,000 exhibitors from 70 countries in 17 halls.

Join EKF Diagnostics at Point of Care: Innovations

Bristol, UK. 20th September 2022